Compare · head to head
Agenus vs CytomX Therapeutics
Agenus ranks higher overall — 360 rank 85 vs 8.
Agenus leads on Value (62 vs 42), Quality (64 vs 38) and Safety (66 vs 31). CytomX Therapeutics leads on Sentiment (57 vs 47).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Small |
| ISIN | US00847G8042 | US23284F1057 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 85 | 8 |
| Value | 62 | 42 |
| Quality | 64 | 38 |
| Growth | NR | 27 |
| Safety | 66 | 31 |
| Sentiment | 47 | 57 |
| Quality details | ||
| Profitability | 74 | 47 |
| Cash Truth | 53 | 28 |
Agenus vs Voyager TherapeuticsAgenus vs Caribou BiosciencesAgenus vs Celldex TherapeuticsAdd a third stock →
Full analyses: Agenus · CytomX Therapeutics
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100